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Abstract
Background: Inhibition of the activated epidermal growth factor receptor (EGFR) with either enzymatic kinase
inhibitors or anti-EGFR antibodies such as cetuximab, is an effective modality of treatment for multiple human
cancers. Enzymatic EGFR inhibitors are effective for lung adenocarcinomas with somatic kinase domain EGFR
mutations while, paradoxically, anti-EGFR antibodies are more effective in colon and head and neck cancers where
EGFR mutations occur less frequently. In colorectal cancer, anti-EGFR antibodies are routinely used as second-line
therapy of KRAS wild-type tumors. However, detailed mechanisms and genomic predictors for pharmacological
response to these antibodies in colon cancer remain unclear.
Findings: We describe a case of colorectal adenocarcinoma, which was found to harbor a kinase domain mutation,
G724S, in EGFR through whole genome sequencing. We show that G724S mutant EGFR is oncogenic and that it
differs from classic lung cancer derived EGFR mutants in that it is cetuximab responsive in vitro, yet relatively
insensitive to small molecule kinase inhibitors. Through biochemical and cellular pharmacologic studies, we have
determined that cells harboring the colon cancer-derived G719S and G724S mutants are responsive to cetuximab
therapy in vitro and found that the requirement for asymmetric dimerization of these mutant EGFR to promote
cellular transformation may explain their greater inhibition by cetuximab than small-molecule kinase inhibitors.
Conclusion: The colon-cancer derived G719S and G724S mutants are oncogenic and sensitive in vitro to cetuximab.
These data suggest that patients with these mutations may benefit from the use of anti-EGFR antibodies as part of
the first-line therapy.
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Activation of the epidermal growth factor receptor
(EGFR) oncoprotein, a member of the ErbB family of re-
ceptor tyrosine kinases, is among the most common
oncogenic driving events in human cancer [1]. Genomic
mechanisms for activating the EGFR gene include nu-
cleotide substitutions and in-frame insertions/deletions
of the kinase domain in lung adenocarcinoma and papil-
lary thyroid carcinomas, and multi-exonic deletions
(exons 2 through 7: EGFR variant III or vIII), nucleotide
substitutions of the extracellular domain and carboxyl
terminal deletions in glioblastoma [2-6]. EGFR is also ac-
tivated by high-copy amplifications in many epithelial
cancer types, prominently in lung and upper gastrointes-
tinal carcinomas as well as glioblastoma and head and
neck cancer [7-10]. Furthermore, EGFR protein is over-
expressed in many cancers even without evidence of fo-
cused genomic alteration, as observed in many cases of
colorectal carcinoma where EGFR kinase domain muta-
tions were found in only 3 out of 224 cases, 1.3% sub-
jected to whole exome sequencing [11,12]. Given the
elevated expression and genomic alterations present in
EGFR, multiple cancer therapies have targeted EGFR, as
both its kinase activity and its dependence on extracellu-
lar ligand signaling have rendered EGFR vulnerable to
therapeutic intervention. FDA-approved EGFR targeted
inhibitors include the low-molecular-weight ATP-
competitive kinase inhibitors, such as gefitinib and erlo-
tinib, and humanized monoclonal antibodies directed
against the extracellular domain, notably cetuximab and
panitumumab [13]. Although high-level expression of
EGFR ligands and/or increased EGFR gene copy num-
bers may be predictive markers for antitumor response
by cetuximab in colon cancer [14-16], and patients with
RAS driven cancers are known not to benefit from
cetuximab treatment, a clear molecular explanation of
cancer response to cetuximab has remained elusive.
Genomic studies identify G724S mutant in
colorectal carcinomas
Colorectal adenocarcinoma has been a classic model to
study the progressive accumulation of genomic lesions
leading to cellular transformation. Key genomic features of
these tumors involve inactivation of tumor suppressors
such as APC, TP53 and SMAD4 and mutational activation
of oncogenes including KRAS, NRAS, BRAF and PIK3CA
[17]. Given the role of cetuximab in therapy of these can-
cers, initial efforts to identify activating EGFR mutations
identified few such events, though potentially activating
events such as G719S were seen [18]. More recent reports
have also identified potentially mutations of ERBB3 [19]
and amplifications and mutations of ERBB2 in CRC
[12,20]. We have previously reported whole genome se-
quence analysis of nine colorectal carcinoma/normal pairs,
leading to the identification of activating translocations of
TCF7L2 and of the association of Fusobacterium nucleatum
with colorectal carcinomas [21,22]. Here, we report genomic
analysis of a tenth anonymized case of colorectal carcinoma.
Whole genome sequencing was performed on the genomic
DNA from colorectal carcinoma tissue and adjacent non-
neoplastic colonic tissue to a median coverage of 32.5x and
34.2x coverage, respectively, with 86.8% of the genome se-
quenced to adequate depth for mutation calling.
An analysis of somatic genome structural alterations
by comparison of tumor-derived and non-neoplastic
derived sequences identified 63 somatic structural
rearrangements, including a deletion of the APC tumor
suppressor gene (Figure 1A, Additional file 1: Figure S1A,
and Additional file 2: Table S1). Comparison of nucleotide
sequences between the colorectal tumor and normal colon
identified an overall mutation rate of 6.7 mutations/Mb in-
cluding 18,401 somatic nucleotide substitutions, and 983
somatic insertions and deletions of<37 bases (Figure 1B
and Additional file 3: Table S2). As observed in other colo-
rectal cancers [21,23,24], mutation analysis identified a
marked elevation in the rate of C to T transitions at CpG
dinucleotides (82/Mb). Analysis of non-synonymous coding
mutations revealed a total of 119 alterations in 116 genes
(Additional file 4: Table S3). Prominent mutations included
a somatic R175H substitution in the TP53 tumor suppres-
sor gene and a somatic G724S substitution in the EGFR
oncogene (Figure 1B and Additional file 1: Figure S1B).
Somatic mutations of common colorectal adenocarcinoma
oncogenes KRAS, BRAF, NRAS and PIK3CA [23] were not
detected.
The absence of both KRAS and BRAF mutations are
common features seen in colorectal cancers that are re-
sponsive to cetuximab [25,26], thus making the EGFR
mutation in this case of particular interest. The somatic
G724S mutation in EGFR occurs at the final glycine of
the GxGxxG nucleotide-binding motif that is essential
for ATP binding and is conserved among all protein ki-
nases (Figure 1C) [27,28]. Substitution of EGFR G719,
the first residue of this motif, to serine, cysteine, or ala-
nine, has been observed in lung adenocarcinomas (~1%),
and one G719S mutant and four G724S mutants have
been reported in colorectal carcinomas that were
sequenced for EGFR (Figure 1C) [18,29] (COSMIC
database). In addition, these EGFR mutations were
found to be mutually exclusive with well known KRAS,
BRAF and PIK3CA oncogenic driver mutations, demon-
strating their potential role in tumorigenesis (COSMIC
database).
Colon-cancer derived G719S and G724S mutants
are oncogenic and sensitive to cetuximab
To determine whether the G724S mutant is oncogenic and
to evaluate its pharmacologic sensitivity, we generated this
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cells. While wild-type EGFR expressing NIH-3T3 cells form
colonies in soft agar only in the presence of ligand, NIH-
3T3 cells that express EGFR G724S form colonies in the
absence of exogenous ligand, as do the lung and colon
cancer-derived G719S mutants (Additional file 1: Figure
S2A) [30]. Furthermore, both G719S and G724S mutants
undergo constitutive tyrosine-phosphorylation, which is
further increased by EGF treatment, whereas phosphoryl-
ation of wild-type EGFR requires induction by EGF
(Additional file 1: Figure S2B). These data demonstrate that
colon-cancer derived G719S and G724S mutants are onco-
genically active in the absence of ligand stimulation.
To test whether G719S and G724S EGFR mutants are
cetuximab-sensitive in vitro, we ectopically expressed these
mutants in Ba/F3 cells, rendering these cells IL-3 independ-
ent but dependent on exogenous oncogenic EGFR signaling
[31]. Ba/F3 cells expressing the colon-cancer derived
G724S mutant and the lung/colon cancer-derived G719S
mutant showed sensitivity to cetuximab with an IC50 value
A Somatic structural rearrangements Somatic mutations
Total across genome
19,384
Total 119 non-synoynmous coding mutations
(116 genes) 
Substitutions,insertions,deletions
EGFR G724S
TP53 R175H
APC deletion
Total 63 rearrangements 
Extracellular Domain Tyrosine Kinase Domain C-terminal Domain
Transmembrane 
Region
B
C
Figure 1 Identification of a somatic EGFR mutation in colorectal adenocarcinoma via whole genome sequencing. (A) Depiction of the
somatic structural rearrangements in this colorectal cancer genome by a Circos plot. The chromosomes are depicted along the circle with
somatic rearrangements depicted in purple (interchromosomal) and green (intrachromosomal), including a deletion at the APC tumor suppressor
locus. (B) Depiction of numbers of candidate mutations and non-synonymous alterations in coding genes, and mutations in known cancer genes,
TP53 and EGFR. (C) Schematic of somatic EGFR mutations found in glioblastoma (green lettering), lung adenocarcinoma (blue lettering) and
colorectal adenocarcinoma (red lettering), with insertions and deletions above the domain structure, and substitution mutations below the
domain structure indicated by red dots.
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mab sensitivity, Ba/F3 cells dependent on EGFR G719S and
G724S mutants were only moderately sensitive to erloti-
nib with an IC50 value of~0.3 μM( A d d i t i o n a lf i l e1 :
Figure S3A), consistent with previous reports on G719X
mutants in vitro and in lung cancer clinical trials
[30-33] and with the failure of a previously identified
patient with EGFR G724S mutant colorectal cancer to
respond to gefitinib [29].
In order to further examine the efficacy of cetuximab, we
expanded our studies by generating xenograft mouse
models with either SW48 or HCT8 colon cancer cells,
which harbor either EGFR G719S or KRAS G13D muta-
tion, respectively. Here, we found that consistent with
in vitro response (Additional file 1: Figure S3B), cetuximab
treatment dramatically suppressed tumor formation driven
by SW48 cells (Figure 2B), suggesting the anti-tumor effect
of cetuximab against tumors harboring EGFR G719S
mutant. In contrast, cetuximab treatment was ineffective
for the tumors driven by HCT8, which is consistent with
the previous findings that KRAS-mutant tumors are in-
sensitive to cetuximab (Figure 2C). Taken together, we
found that G719S and G724S mutants are oncogenic in the
absence of ligand stimulation and effectively respond to
cetuximab in vivo and in vitro.
Asymmetric dimerization is required for
oncogenic activity of G719S and G724S mutant
Recently, we reported that a subset of lung cancer-
derived oncogenic EGFR mutants such as L858R require
asymmetric dimerization for biochemical activation and
oncogenic transforming activity, meaning that their
oncogenic ability depend on formation of an EGFR ho-
modimer in which two distinct regions of the two mol-
ecule dimerize [34]. By contrast, we showed that other
EGFR mutants are oncogenic without the requirement
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Figure 2 Pharmacological effects of cetuximab against oncogenic G719S and G724S mutants in vitro and in vivo. (A) Cetuximab
suppresses the growth of Ba/F3 cells dependent upon the G719S and G724S mutants, but not control cells. Ba/F3 cells transformed with the
indicated EGFR mutants were treated with cetuximab at the concentrations indicated and assayed for viability after 72 hours of drug treatment.
The results are indicated as mean +/− SD of sextuplicate wells and are representative of three independent experiments (B and C) Cetuximab is
effective against SW48 (EGFR G719S mutant)-induced tumors but not HCT8 (KRAS G13D mutant) induced-tumors in xenografted mice.
BALB/c-nu/nu mice (6–8 weeks of age) were injected subcutaneously to the flank with 0.5~ 1x10
7 SW48 or HCT8 cells in 150~200 μl of PBS.
Tumor sizes were measured two times a week using a Vernier caliper and tumor volumes were calculated according to the formula of (short
diameter)
2 x (long diameter)/2. When tumor volume reached around 100~150 mm
3, mice were randomized into each group. After confirming
that mean tumor volumes were not statistically different between two groups, mice were administered either with PBS or cetuximab
(1 mg/mouse) intra-peritoneally twice a week.
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20 insertion mutant and the T790M mutant [34]. Fur-
thermore, we found that dimerization-dependent L858R
mutant shows a dramatic response to cetuximab,
whereas tumors driven by dimerization-independent
mutants such as T790M are resistant to the antibody,
suggesting that there is a close correlation between
dimerization dependency of lung cancer-derived onco-
genic mutant EGFR and pharmacological effects of
cetuximab [34]. Given that colon cancer-derived G719S
and G724S mutants are sensitive to cetuximab, we
sought to examine whether oncogenic potential of these
mutants are dependent on the asymmetric dimerization
like lung cancer-derived L858R mutant.
To test the hypothesis that cetuximab sensitivity
of G719S and G724S mutants is a function of their
dimerization dependence, we generated G719S and
G724S mutants with compound substitution mutations
at the dimerization interface in the N-lobe or C-lobe
that disrupt the asymmetric dimerization of EGFR [35].
Specifically, we generated epitope-tagged EGFR expres-
sion constructs that combined a receiver-impairing mu-
tation (L704N) and/or an activator-impairing mutation
(I941R) with oncogenic G719S and G724S mutants. The
single or compound EGFR mutants were expressed in
NIH-3T3 cells by retroviral transduction, and the EGFR
mutant-expressing cells were assayed for their ability to
grow in soft agar. In this system, the transforming abil-
ity of dimerization-dependent mutants is predicted to
be abolished by cis mutation of the L704 or I941 muta-
tions. Furthermore, co-expression of the L704N and
I941R mutant forms, in contrast, is predicted to restore
transforming ability that is dimerization-dependent, be-
cause the two mutant forms can heterodimerize. There-
fore, this experiment allows us to test whether specific
EGFR kinase domain mutants can induce cellular
CD
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Figure 3 Dimerization disruption has effects on the transforming activity of G719S and G724S EGFR proteins. (A and B) G719S and
G724S mutants are dependent on asymmetric dimerization for their transforming potential. NIH-3T3 cells expressing the indicated EGFR mutants
with or without receiver-impairing (L704N) or/and activator-impairing (I941R) mutations were assayed for anchorage-independent growth in soft
agar. The bar graph depicts the relative number of colonies in the dimerization-defective mutants normalized to the number of colonies formed
by cells expressing the respective parental mutants (n= 3, mean+SD). (C and D) Ligand-induced and constitutive tyrosine-phosphorylation is
abrogated on dimerization-impaired compound mutants of cetuximab-sensitive EGFR mutants. Whole cell lysates from the same cells analyzed in
Figure 3A and B expressing G719S (C), and G724S (D) mutants with or/and without dimerization-impairing mutations (L704N or I941R) in the
absence or presence of EGF treatment for 15 minutes (25 ng/ml) were subjected to immunoblotting with antibodies against phospho-tyrosine
(4G10) and EGFR.
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pendent fashion.
Dimerization-impairing cis mutations in EGFR,
L704N and I941R, significantly reduced the ability of
the cetuximab-sensitive G719S and G724S mutants to
promote colony formation upon retroviral transduction
(Figure 3A and B, L704N or I941R); colony-forming
activity was partially or completely restored by co-
expression of the L704N and I941R mutants in trans
(Figure 3A and B, L704N&I941R). Consistent with these
results, we found that constitutive and EGF-inducible
autophosphorylation of the G719S and G724S mutants
(Figures 3C and D, lanes 1 and 2), is attenuated by the
introduction of L704N and I941R dimerization-
impairing mutations (Figures 3C and D, lanes 3, 4, 5,
and 6). Furthermore, receptor phosphorylation is par-
tially rescued by co-expression of either G719S/L704N
or G719S/I941R mutants or the cognate combination in
a G724S mutant background (Figure 3C and D, lanes 7
and 8). Taken together, these data suggest that colon
cancer-derived cetuximab-sensitive G719S and G724S
mutants acquire their oncogenic potentials following
asymmetric dimerization, respectively, which are similar
to lung-cancer derived L858R mutant [35]. Further-
more, these results are consistent with our model that
EGFR variants that are dependent on dimerization can
be inhibited by cetuximab.
In summary, our findings suggest that EGFR mutation
may underlie at least some cases of cetuximab responsive-
ness in colorectal carcinoma. While EGFR mutation has
historically been believed to be rare in colorectal carcin-
omas, whole exome sequencing published through The
Cancer Genome Atlas identified somatic non-synonymous
coding EGFR mutations in 10 of 224 colorectal carcinoma
cases (or 4.5%) [12]. While many such mutations may be
passenger alterations that do not activate EGFR signaling,
these results do speak to the potential for mutational activa-
tion of EGFR to result in susceptibility to anti-EGFR anti-
bodies in a small fraction of CRC cases. Indeed, the recent
d e m o n s t r a t i o no fs e c o n d a r ys o m a t i cm u t a t i o ni nt h eE G F R
extracellular domain conferring acquired resistance to
cetuximab [36] is consistent with attribution of responses
to cetuximab to EGFR blockade. Anti-EGFR therapy in
metastatic colorectal cancer has been reserved for second-
line therapy after failure of initial empiric chemotherapy
but is now increasingly also used as part of first-line therapy
for RAS wild-type patients. As genomic diagnostics enter
into routine clinical practice, patients whose CRCs harbor
potentially oncogenic EGFR mutations will be identified, in-
cluding those at codons 719 and 724. These results suggest
that in such patients, therapeutic approaches utilizing
EGFR-directed antibody as part of their initial therapy
should be evaluated given the greater potential dependence
on EGFR signaling in these patients.
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